I have a twitter thread that’s going viral on Xocova, a SARS-CoV-2 antvirial drug that’s been approved in Japan since 2022, and was recently approved for post-exposure prophylactic use in Japan. The FDA has been reviewing the drug for about 9 months, and they’re targeting a decision in June.

I’m wondering if I should convert the thread into a Substack post, or if just a Substack Note on it is better. To create the thread it took about five hours to research, write, and create the graphics! x.com/moreisdifferent/s…